Media stories about Galena Biopharma (NASDAQ:GALE) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Galena Biopharma earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.5757542607129 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
Separately, Maxim Group reaffirmed a “hold” rating on shares of Galena Biopharma in a research note on Wednesday, August 9th.
Galena Biopharma (NASDAQ GALE) traded down 3.4943% during trading on Thursday, hitting $0.3397. 295,660 shares of the stock were exchanged. Galena Biopharma has a 12-month low of $0.26 and a 12-month high of $6.10. The stock has a 50 day moving average price of $0.37 and a 200-day moving average price of $0.49. The firm’s market capitalization is $13.05 million.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). During the same period in the previous year, the company earned $0.05 EPS. On average, equities research analysts anticipate that Galena Biopharma will post ($0.59) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Galena Biopharma (GALE) Stock Price” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/26/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-galena-biopharma-gale-stock-price.html.
About Galena Biopharma
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.